

## DAFTAR PUSTAKA

- Aknin SB, Cuvelier MF, Eymard B. 2014. Diagnostic and clinical classification of autoimmune myasthenia gravis. *Journal of autoimmunity*; xxx: 1-6.
- Alahgholi HM, Oflazer P, Aysal F, Durmuş H, Gülşen PY, Marx A, *et al.* 2015. Regulatory function of CD4+ CD25+ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity. *J Neuroimmunol*; 281:51–60.
- Amir D. 2012. Neurotransmitter faktor penentu kekuatan dan kelemahan seseorang. Jakarta: Penerbit Bandung Sains dan Teknologi, hal: 28-47.
- Aurangzeb S, Tariq M, Irshad M, Badshah M, Kan RS. 2009. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. *J Pak Med Assoc*;59: 290-292.
- Aydin Y, Ulas AB, Mutlu V, Colak A, Eroglu A. 2017. Theymectomy in myasthenia gravis. *Eurasian J Med*; 49: 48-52.
- Baggi F dan Mantegazza F. 2014. European database for myasthenia gravis: a model for an international disease registry. *Neurology*; 83: 189-191.
- Baratawidjaja KG. 2006. *Imunologi dasar*. Edisi 7. Jakarta: Balai Penerbit FK UI, hal: 70-202.
- Barnet C, Katzberg H, Nabawi M, Bril V. 2012. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers. *J Clin Neuromusc Dis*; 13: 201-205.
- Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A. 2006. Anti-Musk antibodies: correlation with myasthenia gravis severity. *Neurology*; 67: 505-507.
- Benatar M. 2006. A systmatic review of diagnostic studies in myasthenia gravis. *Neuromuscular Disorder*; 16: 459-467.
- Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. 2016. Epidemiology of myasthenia gravis in ontario, canada. *Neuromuscul Disord*; 26(1): 41-6.
- Burns. 2012. Myasthenia gravis. In *Netter's Neurology*, 2<sup>nd</sup> Edition; 73: 684-702.
- Conti-fine BM, Milani M, Kaminski HJ. 2006. Myasthenia gravis: past, present, and future. *J Clin Invest*; 116(11): 2843-54.

- Darwin E. 2006. Imunologi dan infeksi. Padang: Andalas University Press, hal:46-173.
- Dhein S, van Koppen CJ, Brodde O. Muscarinic receptors in the mammalian heart. *Pharmacol. Res.* 2001 Sep;44(3):161-82.
- Engel AG. 2013. Myasthenia gravis an myasthenic disorders. 2nd Edition. United Kingdom: Oxford University Press, pp: 85-233.
- Eric M, Eliahu S, Feen, Jose I. 2008. Myasthenia gravis crisis. *Southern Medical Journal*; 101(1): 69-63.
- Erwin I dan Kusuma DI. 2012. Inhibitor asetilkolinesterase untuk menghilangkan efek relaksan otot non-depolarisasi. *CDK-193*; 39(5): 333-339.
- Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V et al. 2014. Anti-agrin autoantibodies in myasthenia gravis. *Neurology*; 82(22): 1976-83.
- Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. 2016. Myasthenia gravis-autoantibody characteristic and their implications for therapy. *Neurology*; 12(5): 259-68.
- Gold CS, Hagenacker T, Melzer N, Ruck T. 2019. Understanding the burden of refractory myasthenia gravis. *Ther Adv Neurol Disord*; 12: 1-16.
- Gomez AM, Van Den Broeck J, Vrolix K, et al. 2010. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. *Autoimmunity*, 43(5-6):353-70.
- Gratton SM, Herro AM, Feuer WJ, Lam BL. 2016. Cigarette smoking and activities of daily living in ocular myasthenia gravis. *J Neuro-Ophthalmol*; 36: 37-40.
- Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, et al. 2016. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. *Autoimmunity*, *Eraly Online*: 1-8.
- Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, et al. 2012 Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. *Nature*; 482(7386):547-51.
- Hakim M, Safri AY, Wiratman W. 2017. Miastenia gravis. Dalam Buku Ajar Neurologi Buku 2. Jakarta: Penerbit Kedokteran Indonesia, hal: 741-754.
- Hakim M, Gunadharma S, Basuki M. 2018. Pedoman tatalaksana GBS, CIDP, MG imunoterapi. Jakarta: Penerbit Kedokteran Indonesia, hal: 41-55.

- Hehir MK, Silvestri NJ. 2018. Generalized myasthenia gravis classification, clinical presentation, natural history, and epidemiology. *Neurol Clin*; 36: 253-260.
- Heldal AN, Eide GE, Romi F, Owe JF, Gilhus NE. 2014. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. *PLOS ONE*; 9(12): 1-11.
- Huijbers MG, Lipka AF, Plomp JJ, Niks EH, van der Maarel SM, Verschuuren JJ. 2014. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. *J Intern Med*, 275(1):12-26.
- Jacob S, Viegas S, Lashley D, Jones DH. 2009. Myasthenia gravis and other neuromuscular junction disorder. *Neurology in Practice*; 9: 364-371.
- James FH. Epidemiology and Pathophysiology. 2008. In: *Myasthenia gravis a manual for health care provider*. 1st Edition. USA: Myasthenia Gravis Foundation of America; pp:8-14.
- Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keeseey JC, Penn AS *et al*. 2000. Myasthenia gravis recommendation for clinical research standards. *Neurology*; 55: 16-23.
- Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A, *et al*. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. *FEBS J*. 2007 Aug;274(15):3799-845.
- Kang SY, Oh JH, Song SK, Lee JS, Choi JC Kang JH. 2015. Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. *Neurol Sci*; 36(7): 1167-71.
- Karlin A. 2002. Emerging structure of the nicotinic acetylcholine receptors. *nature review neuroscience*; 3: 102-114.
- Kim JY, Park KD, Richman DP. 2011. Treatment of myasthenia gravis based on its immunopathogenesis. *J Clin Neurol*; 7: 173-183.
- Kresno SB. 2010. *Imunologi: diagnosis dan prosedur laboratorium*. Edisi 4. Jakarta: Penerbit FK UI, hal: 4-38.
- Kurniani N. 2012. Manajemen terkini miastenia gravis. Dalam *Neurological Update*, Ed 1. Jakarta: Perpustakaan Nasional: Katalog Dalam Terbitan, hal:71-81.
- Limburg PC, The TH, Tappel EH, Oosterhuis HJ. 1983. Anti-acethylcholine receptor antibodies in myasthenia gravis. Part I relation to clinixal parameters in 250 patients. *Journal of Neurological Sciences*; 58: 357-370.

- Lisak RP. 1999. Myasthenia gravis. *Curr Treat Options Neurol*; 1(3): 239-250.
- Longstaff A, 2007. Memory and cognition. *Dalam Neurosciences 2nd ed.* New York: Taylor & Francis Group, pp:99-101
- Marcus F, Losen M, Martinez PM, Damoiseaux J, Hoeijmakers J, Hochstenbag M et al. 2017. Acetylcholine receptor antibody levels correlate with clinical status in myasthenic thymomas and non-thymomas. *Mediastinum*; 1: AB026.
- Mantegazza R, Bernasconi P, Cavalcante P. 2018. Myasthenia gravis: from autoantibody to therapy. *Curr Opin Neurol*; 31(5): 517-525.
- Melzer N, Ruck T, Fuhr P, Gold R, Hohfeld R, Marx A *et al.* 2016. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of German Neurological Society. *J Neurol*; 263(8): 1473-94.
- Meriggioli MN, Sanders DB. 2012. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. *Expert Rev Clin Immunol*, 8(5):427-38.
- Naira R. 2010. *Imunologi. Dalam Mikrobiologi Kedokteran Jawetz, Melnick & Adelberg. Edisi 25.* Jakarta: EGC, hal:125-48.
- Oosterhuis HJG, Limburg PC, Tappel EH, The TH. 1983. Anti-acetylcholine receptor antibodies in myasthenia gravis. *Journal of neurological sciences*; 58: 371-385.
- Park SY, Lee JY, Lim NG, Hong YH. 2016. Incidence and prevalence of myasthenia gravis in Korea: a population-based study using the National Health Insurance claims database. *J Clin Neurol*; 12(3): 340-4.
- Pascuzzi RM. 2001. Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. *Seminars in Neurology*, vol 21(4): 425-440.
- Peeler CE, Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. 2015. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. *Jama Neurology*: E1-E5.
- Preston CD dan Shapiro B. 2013. Electromyography and neuromuscular disorders. *Clinical Electrophysiologic Correlation. Third edition.* pp:52-61.
- Romi F, Skeie GO, Aarli JA, Gilhus NE. 2000. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. *Arch Neurol*; 57(11): 1596-600.
- Romi F dan Gilhus NE. 2005. Myasthenia gravis clinical, immunological, and therapeutic advances; 111: 134-41.

- Sadalage G, Torane P, Karim A, Jacob S. 2016. What influences false positiveachr antibody results?. *J Neurol Neurosurg Psychiatry*; E1-2.
- Sanders DB, Tucker LB, Massey JM. 2003. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. *Annals of the New York Academy of Sciences*; 998: 440-4.
- Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Webb LH et al. 2014. Does change in acethylcoline receptor antibody level correlate with clinical change in myasthenia gravis?. *Muscle Nerve*; 49(4): 483-6.
- Sathasivam S. 2008. Steroids and immunosuppressant drugs in myasthenia gravis. *Nature Clinical Practice Neurology*; 4(6): 317–327.
- Savarese JJ. 2002. A current practice of relaxation. In: *Clinical Anesthesiology*, 3rd ed. McGraw-Hill, pp:10-19.
- Somnier FE. 1993. Clinical implementation of anti-acetylcholine receptors antibodies. *J Neurol Neurosurg Psychiatry*; 56(5): 496-504.
- Thanvi BR dan Lo TC. 2004. Update on myasthenia gravis. *Postgrad Med J*; 80: 690-700.
- Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. 2012. Myasthenia gravis: a review. *Autoimmune Dis*; 2012: 1-10.
- Wang Z dan Yan Y. 2017. Immunopathogenesis in myasthenia gravis and neuromyelitis optica. *Front Immunol*; 8: 1785.
- Wiratman W, Safri AY, Indrawati LH, Sutanto A, Soebroto AD Fadhli H dkk. 2016. Profil miastenia gravis di RSUPN Cipto Mangunkusumo: awal sebuah registri nasional. Jakarta: Baan Penerbit FK UI, hal: 96-101.
- Webster RA. 2001. *Neurotransmitter, Drug and Brain Function*. London: John wiley&Sons Ltd, pp: 117-86
- Zagoriti Z, Kambouris ME, Patrinos GP, Tzartos S, Poulas K. 2013. Recent advanced in genetic predisposition of myasthenia gravis. *BioMed Reasearch International*; 2013: 1-13.